Acadia Pharma (ACAD) Tops Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Acadia Pharma (ACAD) Tops Q4 EPS by 2c

ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 26, 2020 4:05 PM EST

- Full Year 2019 Net Sales Grew to $339.1 Million, a 52% Increase over Full Year 2018

- 2020 Net Sales Guidance of $440 to $470 Million

- On-Track to Submit Supplemental New Drug Application for Dementia-Related Psychosis in Summer 2020

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2019.

In 2019 ACADIA demonstrated strong execution from our commercial and R&D teams, driving the continued growth of NUPLAZID and advancing our late-stage pipeline, said Steve Davis, Chief... More